This clinical trial is testing an investigational injectable medication for patients diagnosed with cirrhosis due to MASH (Non-Alcoholic/Metabolic Dysfunction-Associated Steatohepatitis).

Converts on qualified lead submission

Targeting: Consumers aged 18–80 who have a physician diagnosis of liver cirrhosis caused by MASH. Qualified participants must not have serious complications of cirrhosis (like treated ascites or variceal bleeding) or a history of other specific liver conditions (e.g., Hepatitis B/C, Alcoholic liver disease).

Restrictions: ALL COPY AND CREATIVE must be submitted for compliance approval before going live. Live GEOs must be confirmed via the provided link: Live Geos. No incentive traffic is permitted.